309 related articles for article (PubMed ID: 30582270)
1. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
2. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
3. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
4. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
[TBL] [Abstract][Full Text] [Related]
5. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
Everly MJ; Roberts M; Townsend R; Bray RA; Gebel HM
Am J Transplant; 2018 Sep; 18(9):2305-2313. PubMed ID: 29767445
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
[TBL] [Abstract][Full Text] [Related]
7. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
8. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
[TBL] [Abstract][Full Text] [Related]
9. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
10. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
11. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
[TBL] [Abstract][Full Text] [Related]
12. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
15. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
18. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
Florman S; Vincenti F; Durrbach A; Abouljoud M; Bresnahan B; Garcia VD; Mulloy L; Rice K; Rostaing L; Zayas C; Calderon K; Meier-Kriesche U; Polinsky M; Yang L; Medina Pestana J; Larsen CP
Clin Transplant; 2018 Apr; 32(4):e13225. PubMed ID: 29461660
[TBL] [Abstract][Full Text] [Related]
19. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials.
Lange NW; King K; Husain SA; Salerno DM; Tsapepas DS; Hedvat J; Yu M; Mohan S
Am J Transplant; 2024 Jun; 24(6):1027-1034. PubMed ID: 38387620
[TBL] [Abstract][Full Text] [Related]
20. Increased Pretransplant Frequency of CD28
Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]